NasdaqGS - Delayed Quote • USD
Neurocrine Biosciences, Inc. (NBIX)
At close: April 26 at 4:00 PM EDT
After hours: April 26 at 5:10 PM EDT
Earnings Estimate
CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
---|---|---|---|---|
No. of Analysts | 18 | 17 | 18 | 18 |
Avg. Estimate | 1.01 | 1.18 | 4.77 | 6.41 |
Low Estimate | 0.18 | 0.89 | 3.82 | 4.58 |
High Estimate | 1.77 | 1.67 | 5.72 | 8.58 |
Year Ago EPS | -0.79 | 0.95 | 2.47 | 4.77 |
Revenue Estimate
CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
---|---|---|---|---|
No. of Analysts | 24 | 22 | 26 | 26 |
Avg. Estimate | 511.97M | 545.66M | 2.21B | 2.58B |
Low Estimate | 491.5M | 529M | 2.14B | 2.26B |
High Estimate | 528M | 581M | 2.36B | 3.78B |
Year Ago Sales | 409.26M | 447.31M | 1.89B | 2.21B |
Sales Growth (year/est) | 25.10% | 22.00% | 17.40% | 16.50% |
Earnings History
CURRENCY IN USD | 3/31/2023 | 6/30/2023 | 9/30/2023 | 12/31/2023 |
---|---|---|---|---|
EPS Est. | 0.13 | 0.78 | 0.97 | 1.14 |
EPS Actual | -0.79 | 0.95 | 0.82 | 1.44 |
Difference | -0.92 | 0.17 | -0.15 | 0.3 |
Surprise % | -707.70% | 21.80% | -15.50% | 26.30% |
EPS Trend
CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
---|---|---|---|---|
Current Estimate | 1.01 | 1.18 | 4.77 | 6.41 |
7 Days Ago | 0.99 | 1.18 | 4.78 | 6.4 |
30 Days Ago | 1 | 1.19 | 4.8 | 6.29 |
60 Days Ago | 1 | 1.19 | 4.79 | 6.3 |
90 Days Ago | 1.07 | 1.18 | 4.76 | 6.45 |
EPS Revisions
CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
---|---|---|---|---|
Up Last 7 Days | 2 | 2 | 2 | 2 |
Up Last 30 Days | 6 | 5 | 5 | 7 |
Down Last 7 Days | -- | -- | -- | -- |
Down Last 30 Days | 4 | 3 | 3 | 4 |
Growth Estimates
CURRENCY IN USD | NBIX | Industry | Sector | S&P 500 |
---|---|---|---|---|
Current Qtr. | 227.80% | -- | -- | 6.50% |
Next Qtr. | 24.20% | -- | -- | 12.00% |
Current Year | 93.10% | -- | -- | 5.30% |
Next Year | 34.40% | -- | -- | 13.10% |
Next 5 Years (per annum) | 18.00% | -- | -- | 11.09% |
Past 5 Years (per annum) | 22.55% | -- | -- | -- |
Research Analysis
Upgrades & Downgrades
Upgrade | Wells Fargo: Equal-Weight to Overweight | 4/24/2024 |
Maintains | Oppenheimer: Outperform to Outperform | 4/24/2024 |
Reiterates | HC Wainwright & Co.: Buy to Buy | 4/24/2024 |
Reiterates | Needham: Hold | 4/23/2024 |
Reiterates | Wedbush: Outperform to Outperform | 4/17/2024 |
Reiterates | Cantor Fitzgerald: Overweight to Overweight | 4/10/2024 |
Related Tickers
ITCI Intra-Cellular Therapies, Inc.
73.26
+1.57%
ALKS Alkermes plc
24.68
+0.98%
TAK Takeda Pharmaceutical Company Limited
13.03
-0.31%
AQST Aquestive Therapeutics, Inc.
4.0700
+3.56%
IRWD Ironwood Pharmaceuticals, Inc.
7.82
-3.22%
DVAX Dynavax Technologies Corporation
11.21
+0.36%
AVDL Avadel Pharmaceuticals plc
17.81
-0.06%
RDY Dr. Reddy's Laboratories Limited
74.55
+0.72%
EVO Evotec SE
5.02
-1.57%
LNTH Lantheus Holdings, Inc.
65.56
+0.55%